🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. SAR443765 / LUNSEKIMIG, Matched Placebo to Test, MOMETASONE

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases

    phase 2 small molecule active

    1 trial

  2. SAR444656, Matched Placebo

    Sanofi Pharma Bristol-Myers Squibb

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  3. SAR445761 - belumosudil, belumosudil

    Sanofi Pharma Bristol-Myers Squibb

    Chronic graft versus host disease.

    phase 2 small molecule active

    1 trial

  4. Sodium Chloride 0.9%, INBRX-101 Concentrate for Solution for Infusion 50mg/ml, Respreeza 1,000 mg powder and solvent for solution for infusion.

    Sanofi Pharma Bristol-Myers Squibb

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  5. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  6. Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion

    Sanofi Pharma Bristol-Myers Squibb

    Solid tumor

    phase 2 small molecule active

    1 trial

  7. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  8. farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  10. riliprubart

    Sanofi Pharma Bristol-Myers Squibb

    Chronic inflammatory demyelinating polyradiculoneuropathy

    phase 2 small molecule active

    1 trial

  11. riliprubart, riliprubart

    Sanofi Pharma Bristol-Myers Squibb

    Transplant Rejection

    phase 2 small molecule active

    1 trial

  12. sarilumab

    Sanofi Pharma Bristol-Myers Squibb

    Systemic Juvenile Idiopathic Arthritis (sJIA)

    phase 2 small molecule active

    1 trial

  13. A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

    Bristol-Myers Squibb / Pfizer EEIG

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  14. A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  15. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  16. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  17. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb / Pfizer EEIG

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  18. A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 1 other active

    1 trial

  19. A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  20. A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS

    Bristol-Myers Squibb / Pfizer EEIG

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  21. A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

    Sanofi Pharma Bristol-Myers Squibb

    Osteoarthritis

    phase 1 other active

    1 trial

  22. A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers

    Pharma Mar S.A.

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  23. A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

    Sanofi Pharma Bristol-Myers Squibb

    Immune Thrombocytopenia Purpura

    phase 1 other active

    1 trial

  24. A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources